. Author manuscript; available in PMC: 2021 Jul 16.

Published in final edited form as: J Biomol Screen. 2012 Apr 24;17(7):957–965. doi: 10.1177/1087057112444927

Table 1.

Summary of GUS Inhibitory Activity of Studied Drugs

Drug	Drug Class	Currently Marketed	E. coli GUS Enzyme Assay^a	B. taurus GUS Enzyme Assay^a	E. coli Cell-Based Assay^a
Drug	Drug Class	Currently Marketed	IC₅₀ ± SD (nM)	IC₅₀ ± SD (nM)	IC₅₀ ± SD (nM)
Nialamide	Irreversible MAOI	No	71 ± 32	74,813 ± 1,841	17 ± 2
Isocarboxazid	Irreversible MAOI	Yes	128 ± 56	>100,000	336 ± 120
Phenelzine	Irreversible MAOI	Yes	2,282 ± 1041	ND^b	7,123 ± 1650
Amoxapine	Tricyclic Antidepressant	Yes	388 ± 98	>100,000	119 ± 61
Loxapine^c	Tricyclic Antidepressant	Yes	>100,000	ND	>100,000
Mefloquine	Antimalarial	Yes	1,212 ± 234	ND	5,961 ± 1526

IC₅₀ value determinations were performed at least three times, with average IC₅₀ values and standard deviations (SD) shown. The range of average Hill slopes for all measurable IC₅₀ curves (where at least 50% inhibition was obtained) was 0.84 to 1.26.

ND = not determined;

This drug was included as a study control